Statement 21: The efficacy of potassium-competitive acid blockers is comparable to proton pump inhibitors; hence they are recommended as an initial treatment of gastroesophageal reflux disease.      Level of evidence: moderate      Strength of recommendation: strong      Experts’ opinions: agree strongly (66.7%), agree with some reservations (33.3%), undecided (0.0%), disagree (0.0%), and disagree strongly (0.0%)